DEF 14A: Ovid Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Ovid Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Ovid Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders virtually on Thursday, June 6, 2024, at 10:00 a.m. Eastern time.
• Stockholders can attend, ask questions, and vote their shares online at www.virtualshareholdermeeting.com/OVID2024 using a 16-digit control number.
• The meeting will address the election of directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining eligible voters is April 9, 2024.
• The Board of Directors recommends voting for the election of the director nominees, for the advisory vote on executive compensation, and for the ratification of the selection of KPMG LLP.
• Stockholders can vote online, by telephone, or by mail, with specific deadlines for each method.
• The company's Board consists of six directors, divided into three classes with three-year terms.
• Barbara Duncan and Robert Michael Poole are nominated for election as Class I directors.
• The Board has determined that all directors, except Dr. Levin, are independent.
• The company has a Code of Business Conduct and Ethics, Corporate Governance Guidelines, a Hedging Policy, and a Clawback Policy.
• Stockholders can communicate with the Board through a formal process outlined on the company's website.
• The company's executive compensation structure is designed to align executive performance with long-term value creation for stockholders.
• The company maintains a 401(k) retirement plan for its employees.
• Non-employee directors receive an annual base retainer of $40,000, with additional compensation for committee service.
• The company has a Related Person Transactions Policy to review and approve related-party transactions.
• The company provides indemnification for its directors and executive officers.
• As of April 9, 2024, there were 70,810,661 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the company's commitment to corporate governance and transparency, while the lack of specific financial performance data keeps the sentiment from being higher.

Positives

• The company is providing stockholders with the ability to attend and participate in the Annual Meeting virtually, increasing accessibility and lowering costs.
• The Board has implemented various corporate governance policies, including a Code of Business Conduct and Ethics, Corporate Governance Guidelines, and a Clawback Policy, promoting ethical behavior and accountability.
• The company's executive compensation structure is designed to align executive performance with long-term value creation for stockholders.
• The company maintains a 401(k) retirement plan for its employees, providing a valuable benefit.
• The company has a Related Person Transactions Policy to ensure fair and transparent dealings with related parties.

Future Outlook

The Board knows of no other business to be brought before the 2024 Annual Meeting which is not referred to in the accompanying Notice of Annual Meeting. Should any such matters be presented, the persons named in the proxy shall have the authority to take such action in regard to such matters as in their judgment seems advisable.

Management Comments

• Jeremy M. Levin, DPhil, MB BChir, Chief Executive Officer: 'On behalf of the Board of Directors and the employees of Ovid, we appreciate your investment in Ovid and urge you to cast your vote as soon as possible.'

Industry Context

This proxy statement is a standard document for publicly traded companies, outlining the matters to be voted on at the annual meeting and providing information to stockholders to make informed decisions. The topics covered, such as director elections, executive compensation, and auditor ratification, are typical for such meetings.

Comparison to Industry Standards

• The structure of the board with classified directors is a common practice among publicly traded companies, especially in the biotech industry.
• The compensation packages for executives and non-employee directors are generally in line with industry standards, considering the company's size and stage of development.
• The use of independent compensation consultants to assess executive and director compensation is a best practice followed by many companies.
• The presence of a clawback policy is increasingly common due to regulatory requirements and investor expectations.

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, as they relate to the election of directors, executive compensation, and the selection of the company's auditor.
• Employees may be indirectly impacted by the executive compensation decisions and the overall corporate governance practices of the company.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals by the specified deadlines.
• The company will hold the Annual Meeting on June 6, 2024, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, KPMG LLP, Corporate Governance, Ovid Therapeutics, Voting